This 150-page report provides an overview of the global remote patient monitoring (RPM) market. The research in this report is based on the remote patient monitoring (RPM) market. It is a complete overview of the market, covering all aspects of the current market structure. It has accumulated comprehensive information and research methods. The Remote Patient Monitoring (RPM) market research report is a detailed investigation of the current market conditions, covering multiple market dynamics.
In 2019, the global remote patient monitoring (RPM) market was worth 16.54 billion U.S. dollars and is expected to reach 195.91 billion U.S. dollars by 2027, growing at a compound annual growth rate of 36.2% during the forecast period.
According to market report analysis, remote patient monitoring (RPM) is a technology used to collect medical and health-related data from individuals in one location and transmit it electronically to healthcare providers in another location. RPM is used to remotely monitor and analyze physiological parameters, such as blood oxygen level, vital signs, blood pressure, heart rate, and blood sugar, thereby improving the quality of care and quality of life, and predicting deterioration and deterioration early. This reduces the number of emergency room visits and the length of hospital stay.
Some of the most important key factors driving the growth of the global remote patient monitoring (RPM) market are advances in telecommunications and increased investment in telemedicine and remote patient monitoring. However, the informal use of social media practices is hindering market growth.
This comprehensive remote patient monitoring (RPM) market research report from 2019 to 2027 briefly introduces these trends and can help companies in this industry understand the market and formulate business expansion strategies accordingly. The research report analyzes the market size, industry share, growth, key market segments, compound annual growth rate and key driving factors.
In-depth analysis of the impact of COVID-19 on the remote patient monitoring (RPM) market in 2021 | We will customize the report according to your requirements-get it now! !
Apply for a discount on the standard price of this premium report @ https://marketprognosis.com/discount-request/20399.
GE Healthcare (May 10, 2021)-GE Healthcare has launched a new virtual solution with AI-enabled nuclear medicine precision health applications-to help nuclear medicine clinicians provide greater flexibility and For more patient time, GE Healthcare today launched Xeleris V-a new virtual processing and review solution. Xeleris V eliminates the need for a standalone nuclear medicine workstation, so clinicians can safely access data from different locations. This increase in visits, combined with new AI-enabled applications and GE Healthcare’s huge nuclear medicine camera installation base, can simplify and enhance workflows, helping clinicians quickly and accurately identify, diagnose, and treat patients.
“As we work to rebuild, restore, and reimagine the healthcare of the future, we believe that artificial intelligence will play a key role in helping the healthcare system maximize the use of resources to provide personalized care faster and easier,” the molecule Jean-Luc Procaccini, President and CEO of Imaging and Computing, explained tomography, GE Healthcare. “Xeleris V helps to do this by providing clinicians with a new way of working, allowing them more time to accompany their patients, and helping them to use the latest innovative technology on all devices for fast and confident diagnosis.”
Market research shows that 73% of radiologists expect operational efficiency to be a major challenge in the next 1-3 years, while 64% of clinicians surveyed pointed out that doctor burnout has increased during the pandemic. These statistics highlight today’s growing need to improve the flexibility, accessibility, and efficiency of healthcare.
“No one wants to click on windows on a workstation all day, but today’s manual workflows (such as organ segmentation) are time-consuming, tedious, and highly operator-dependent,” explains Avi, Professor of Medicine, MD, and Ph.D. Director of the Nuclear Medicine Department of Mori Hospital. “Automating these workflows and easily obtaining repeatable and accurate results is critical to providing high-quality patient evaluation and treatment.”
Xeleris V eliminates the limitations of traditional nuclear medicine workstations, and provides clinicians with a virtual and flexible artificial intelligence-driven solution that allows clinicians to securely access data from anywhere—helping them make personalized Nursing decision-making and treatment recommendations are the core of precise health.
“With artificial intelligence-based technology, we have gained speed, confidence, and repeatability-it changes the radiography process by providing precise results, helping to expand the use of nuclear medicine to personalize patient treatment pathways,” Professor Susang added that his nuclear medicine Avicen Hospital team evaluated GE Healthcare’s new Q. Lung AI solution. “Even in my own practice, I have observed that as we gain the confidence of the surgical team by providing precise results, we have the opportunity to be more involved in guiding the personalized care provided to each patient.”
PharmiWeb.com is Europe’s leading pharmaceutical industry sponsored portal, providing the latest jobs, news, features and events list. The information provided on PharmiWeb.com is intended to support rather than replace the existing patient/patient relationship. The site visitor and his/her doctor.
Disclaimer: You are now leaving the PharmiWeb.com website and going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.
PharmiWeb.com provides links to other third-party websites that may be of interest to visitors to our website. The links provided in our website are only for your convenience and can help you find other useful information on the Internet. When you click on these links, you will leave the PharmiWeb.com website and be redirected to another site. These sites are not under the control of PharmiWeb.com.
PharmiWeb.com is not responsible for the content of linked third-party websites. We are not an agent of these third parties, nor do we endorse or guarantee their products. We make no representations or warranties regarding the accuracy of the information contained in the linked sites. We recommend that you always verify the information obtained from the linked website before taking action based on this information.
In addition, please note that the security and privacy policies on these sites may be different from those of PharmiWeb.com, so please read the third-party privacy and security policies carefully.
If you have any questions or concerns about the products and services provided on the linked third-party website, please contact the third party directly.
Post time: Jun-17-2021